SITC Poster Presentation: “An Immune-CRISPRomics platform enabling genome-scale and pair-wise combination in vivo T-cell function screens enables comprehensive identification of novel therapeutic targets”

by s2desi5_ksqtherapeutics | Nov 9, 2019 | Uncategorized

Click to download PDF file.

KSQ Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference and Provide Updates on Immuno-Oncology and Cell Therapy Programs

by s2desi5_ksqtherapeutics | Dec 3, 2019 | Uncategorized

Lead program declared as small molecule inhibitor of novel target in DDR pathway for the treatment of ovarian and breast cancers CAMBRIDGE, Mass., December 3, 2019 – KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to...

MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ’s Adoptive Cell Therapy Programs

by s2desi5_ksqtherapeutics | Dec 4, 2019 | Uncategorized

Gaithersburg, MD and Cambridge, MA – December 4, 2019: MaxCyte, the global cell-based therapies and life sciences company, and KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to achieve higher probabilities of success in...

KSQ Therapeutics Announces Discovery of Gene Targets with Potential Activity Superior to PD-1 for Development of Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapies for Solid Tumors

by s2desi5_ksqtherapeutics | Feb 9, 2020 | Uncategorized

Data demonstrate potential to increase efficacy of TIL adoptive cell therapy in preclinical models CAMBRIDGE, Mass., February 9, 2020 – KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole...

ASGCT Poster Presentation: “Systematic identification of potent guide RNAs with minimal off-target activity for the CRISPR/Cas9 engineering of KSQ-001, and engineered Tumor Infiltrating Lymphocyte (eTIL™)”

by s2desi5_ksqtherapeutics | May 12, 2020 | Uncategorized

Click to download PDF file.